BIOMARIN PHARMACEUTICAL INC OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment and Tax
BIOMARIN PHARMACEUTICAL INC (BMRN) reported OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment and Tax of -$8.16 million for the 3-month period ending 2015-09-30, per its 10-Q filed 2015-11-02.
Discontinued › Income Statement › Other Income
us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax · last filed 2015-11-02
- BIOMARIN PHARMACEUTICAL INC oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment and tax for the quarter ending 2015-09-30 was -$8.16M, a 297.15% decline year-over-year.
- BIOMARIN PHARMACEUTICAL INC oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment and tax for the quarter ending 2015-06-30 was -$2.46M, a 211.89% decline year-over-year.
- BIOMARIN PHARMACEUTICAL INC oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment and tax for the quarter ending 2015-03-31 was $11.48M, a 411.63% increase year-over-year.
- BIOMARIN PHARMACEUTICAL INC oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment and tax for the quarter ending 2014-12-31 was -$561.00K.
- BIOMARIN PHARMACEUTICAL INC oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment and tax for fiscal 2014 was $8.02M, a 18.26% decline from fiscal 2013.
- BIOMARIN PHARMACEUTICAL INC oci, debt securities, available-for-sale, unrealized holding gain (loss), before adjustment and tax for fiscal 2013 was $9.81M.
| Period end | OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment and Tax 3 month | OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment and Tax 3 month as first filed | OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment and Tax 6 month | OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment and Tax 9 month | OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment and Tax 9 month as first filed | OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment and Tax 12 month |
|---|---|---|---|---|---|---|
| 2015-09-30 | -$8.16M 10-Q · filed 2015-11-02 | -$10.62M derived: sum of 2 quarters · filed 2015-11-02 | $865.00K 10-Q · filed 2015-11-02 | $305.00K derived: sum of 4 quarters · filed 2015-11-02 | ||
| 2015-06-30 | -$2.46M 10-Q · filed 2015-08-05 | $9.02M 10-Q · filed 2015-08-05 | $8.46M derived: sum of 3 quarters · filed 2015-08-05 | $12.60M derived: sum of 4 quarters · filed 2015-11-02 | ||
| 2015-03-31 | $11.48M 10-Q · filed 2015-05-05 | $10.92M derived: sum of 2 quarters · filed 2015-05-05 | $15.06M derived: sum of 3 quarters · filed 2015-11-02 | $17.25M derived: sum of 4 quarters · filed 2015-11-02 | ||
| 2014-12-31 | -$561.00K derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-02 | $3.58M derived: sum of 2 quarters · filed 2015-11-02 | $5.77M derived: sum of 3 quarters · filed 2015-11-02 | $8.02M 10-K · filed 2015-03-02 | ||
| 2014-09-30 | $4.14M 10-Q · filed 2015-11-02 | $6.33M derived: sum of 2 quarters · filed 2015-11-02 | $8.58M 10-Q · filed 2015-11-02 | $8.58M 10-Q · filed 2014-10-28 | $1.16M derived: sum of 4 quarters · filed 2015-11-02 | |
| 2014-06-30 | $2.20M 10-Q · filed 2015-08-05 | $2.20M 10-Q · filed 2014-07-31 | $4.44M 10-Q · filed 2015-08-05 | -$2.98M derived: sum of 3 quarters · filed 2015-08-05 | $11.69M derived: sum of 4 quarters · filed 2015-08-05 | |
| 2014-03-31 | $2.24M 10-Q · filed 2015-05-05 | -$5.17M derived: sum of 2 quarters · filed 2015-05-05 | $9.49M derived: sum of 3 quarters · filed 2015-05-05 | $11.72M derived: sum of 4 quarters · filed 2015-05-05 | ||
| 2013-12-31 | -$7.42M derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-02 | $7.25M derived: sum of 2 quarters · filed 2015-03-02 | $9.48M derived: sum of 3 quarters · filed 2015-03-02 | $9.81M 10-K · filed 2015-03-02 | ||
| 2013-09-30 | $14.66M 10-Q · filed 2014-10-28 | $16.90M derived: sum of 2 quarters · filed 2014-10-28 | $17.23M 10-Q · filed 2014-10-28 | |||
| 2013-06-30 | $2.23M 10-Q · filed 2014-07-31 | $2.56M 10-Q · filed 2014-07-31 | ||||
| 2013-03-31 | $330.00K 10-Q · filed 2014-05-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |